Kyowa Kirin Responds to the National Institute for Health and Care Excellence (NICE) Decision to Not Provide People Living With Certain Rare Blood Cancers Access to POTELIGEO (mogamulizumab)
two very rare forms of non-Hodgkin lymphoma will not have access to
an innovative systemic treatment following NICE s decision to not recommend mogamulizumab for routine use in the NHS
. Kyowa Kirin is disappointed by this decision but remains committed to finding a resolution with NICE.
The National Institute for Health and Care Excellence (NICE) today published its final appraisal document (FAD) for POTELIGEO
(mogamulizumab) announcing that POTELIGEO will not be made available on the NHS
Better treatment promise for those with rare diseases originalfm.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from originalfm.com Daily Mail and Mail on Sunday newspapers.
DHSC publishes ‘UK Rare Disease Framework’
12th January 2021
The UK’s Department of Health and Social Care (DHSC) has published its ‘UK Rare Disease Framework’, which will aim to continuously improve the lives of people living with rare diseases.
Despite rare diseases being individually uncommon, it is currently estimated that there are over 7,000 rare disease, with new conditions being identified as research advances.
Currently, 1 in 17 people will be affected by a rare disease at some point during their lifetime.
The framework identifies four key priorities for rare diseases care and diagnosis to be addressed over the next five years, which includes: